Floatz logo

su011248

HIV Infection

National Cancer Institute (NCI)Phase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

23 Active assets in the HIV Infection cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
AIDS Malignancy Consortium
Phase 2BBB
Cyclophosphamide
AIDS Malignancy Consortium
Phase 3BB
PREDNISONE TABLETS
City of Hope Medical Center
Phase 2BB
Metformin
Brigham and Women's Hospital
Phase 4BB
Letrozole
Ottawa Hospital Research Institute
Phase 4BB

View all 48 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant
BBB
Indicative ·
75 / 100
View asset →
Pancreatic Neuroendocrine TumorDormant
BB
Indicative ·
69 / 100
View asset →
Renal Cell CarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →